Related by context. All words. (Click for frequent words.) 66 prospective multicenter 62 TAXUS ATLAS 62 placebo controlled Phase III 61 SPIRIT IV 61 multicentre randomized 60 TAXUS V 60 zotarolimus eluting stent 60 randomized multicenter 60 TAXUS IV 60 multicenter clinical 60 Phase IIIb clinical 60 multicenter prospective 59 Randomized Evaluation 59 label multicenter 59 multicenter randomized controlled 59 Phase IIIb 59 multicenter randomized double 59 Phase III randomized 58 multicenter randomized placebo controlled 58 PERSEUS 58 EVEREST II 58 SPIRIT FIRST 58 Multicenter 58 everolimus eluting stent 58 randomized Phase III 58 ENDEAVOR III 58 prospective multicenter randomized 57 phase IIa clinical 57 ENDEAVOR IV 57 Pivotal Trial 57 ASTEROID 57 ENDEAVOR 57 TMC# C# 57 multicenter multinational 57 double blinded randomized 57 SPIRIT III 57 SYNTAX 57 multicenter randomized clinical 57 REALITY Trial 57 Long Lesion 57 placebo controlled Phase 57 phase IIa 57 PRECISE 57 Endeavor drug eluting 57 Phase 1b clinical 57 multicenter phase 56 OLYMPIA registry 56 placebo controlled clinical 56 prospective randomized multicenter 56 sirolimus eluting stent 56 active comparator 56 multicenter randomized 56 randomized controlled Phase 56 multicenter Phase III 56 multicentre randomized controlled 56 EchoCRT 56 NO# [002] 56 prospective randomized controlled 56 controlled multicenter 56 multicentre 56 TG MV 56 TAXUS Element Stent 56 TRANSFORMS 56 Phase Ib clinical 56 ONTARGET 56 viral kinetic 56 PREVAIL 56 randomized controlled multicenter 55 phase IIIb 55 RE LY ® 55 Augment Injectable 55 phase IIb clinical 55 prospective randomized 55 EURIDIS 55 landmark ATHENA 55 Phase 2b kidney transplant 55 Initiated Phase 55 STENT 55 pharmacokinetic PK 55 DASISION 55 Phase III psoriasis 55 multicenter 55 APEX PD 55 paclitaxel eluting stent 55 Prospective Randomized 55 BOLDER II 55 NEVO 55 CUSTOM III 55 PARTNER Trial 55 Endeavor Drug Eluting 55 TAXUS Liberte 55 TAXUS Element Paclitaxel Eluting 55 TM Drug Eluting 54 placebo controlled randomized 54 placebo controlled 54 CUSTOM II 54 randomized Phase 2b 54 Phase III placebo controlled 54 Phase 1b 54 Prospective Randomized Trial 54 melphalan prednisone 54 HORIZONS AMI trial 54 metastatic hormone refractory 54 dose escalation Phase 54 fully bioabsorbable 54 TAXUS TM 54 RE LY 54 randomized controlled clinical 54 multicentre randomized double 54 SORT OUT 54 Phase III Psoriasis 54 ENDEAVOR II 54 evaluating REVLIMID 54 blinded randomized 54 Stenting Trial CREST 54 XIENCE V Everolimus Eluting 54 XIENCE V PROMUS Stent 54 Phase Ib II 54 EINSTEIN DVT 54 Phase 1a clinical 54 Pivotal Study 54 DU #b 53 dose escalation clinical 53 Phase 1a 53 comparing XIENCE V 53 CIMZIA TM certolizumab pegol 53 ROCKET AF 53 PFO migraine 53 Sirolimus eluting 53 RECORD1 53 RE SURGE 53 blind randomized placebo 53 Phase 2a clinical 53 NAVIGATOR 53 BRIM2 53 GetGoal Phase III 53 Edwards SAPIEN valve 53 RESOLUTE clinical 53 ABSORB trial 53 Endeavor Resolute DES 53 Myocardial Infarction Study 53 Edge STudy 53 CALGB # [002] 53 Acute Myocardial Infarction 53 Randomised 53 RE MODEL 53 TAXUS VI 53 RIO Lipids 53 pain palliation 53 plus prednisone 53 GOUT 53 GEM OS1 53 randomized blinded 53 TAXUS Liberte stent 53 Cypher Stent 53 COMFORT II 53 TAXUS Stent 53 Acute Ischemic Stroke 53 PROTECT AF 53 ACCLAIM 53 blind randomized 53 NEVO TM 53 blinded placebo controlled 53 pertuzumab 53 Imprime PGG 53 subanalysis 53 randomized controlled 53 prospective multicentre 53 XIENCE V Stent System 53 drug eluting stent DES 53 paclitaxel eluting stents 53 EDEMA3 53 analgesic efficacy 53 carotid endarterectomy CEA 53 Coronary Stent 53 pharmacokinetic PK study 53 randomized multicentre 53 multinational multicenter randomized 53 relapsing multiple sclerosis 53 blind multicenter 53 Val HeFT 53 nonrandomized 53 Phase IIa clinical 53 ADVANCE PD 53 randomized multicenter trial 53 eluting stent 53 NCT# ClinicalTrials.gov 53 label multicenter Phase 52 oral rivaroxaban 52 AIR CF2 52 teriflunomide 52 Resolute DES 52 PROMUS Element Stent 52 ORBIT II 52 multicenter placebo controlled 52 Carotid Revascularization Endarterectomy vs. 52 Vascugel ® 52 acute coronary syndromes ACS 52 CYPHER R Stent 52 TAXUS Liberté 52 pegylated interferon alfa 2b 52 CCX# B 52 CLARITY study 52 CARE HF 52 pharmacokinetics PK 52 blind randomized multicenter 52 Stenting Trial 52 PRIMO CABG 52 PROMUS TM 52 prospectively defined 52 ENESTnd 52 preclinical efficacy 52 registrational Phase 52 TAXUS 52 multicenter Phase II 52 Pivotal Clinical Trial 52 TAXUS Liberte Stent 52 dabigatran etexilate 52 NEVO RES 52 CLARITY TIMI 52 BOLDER 52 sirolimus eluting 52 ENVISION 52 TAXUS Express Stent 52 Nitinol Stent 52 ADONIS 52 icatibant 52 sirolimus eluting stents 52 CYPHER ® Sirolimus eluting 52 ACTEMRA TM 52 Phase Ib 52 ABSORB clinical 52 BCIRG 52 masked placebo controlled 52 carotid stenting 52 XIENCE 52 XIENCE V stent 52 randomized Phase IIb 52 MEND CABG 52 ILLUMINATE 52 Sirolimus Eluting Coronary Stent 52 non inferiority 52 TAXUS Liberte Long 52 ongoing Phase 1b 52 Sorafenib HCC Assessment 52 REALIZE 52 Drug Eluting Stent System 52 BR.# 52 randomized placebo controlled 52 oral ridaforolimus 51 TMC# r 51 phase Ib 51 treatment naïve genotype 51 MERLIN TIMI 51 stent DES 51 MADIT II 51 Sibutramine Cardiovascular Outcomes 51 rALLy clinical trial 51 ASCOT 51 Cardiac Allograft Rejection 51 Randomized Clinical Trial 51 assessing T DM1 51 Phase 1b trial 51 PRoFESS 51 Sirolimus eluting Coronary Stent 51 RADIANT 51 CYPHER R Sirolimus eluting 51 prospective randomized placebo 51 CORD II 51 REVIVE Diabetes 51 Eluting Coronary Stent System 51 TAXUS stent 51 Liberte TM 51 Phase 2b study 51 fosbretabulin 51 TAXUS Express2 51 Phase Ib IIa 51 metastatic HRPC 51 phase IIb 51 ATTRACT 51 phase 2a 51 recurrent GBM 51 Monitoring ABPM 51 trials RCTs 51 SUCCEED trial 51 RE COVER 51 randomized clinical 51 oral FTY# 51 TEMSO 51 doxorubicin docetaxel 51 noninferiority 51 Prostate AdenoCarcinoma Treatment 51 Endovascular Valve Edge 51 dose regimens 51 multicenter Phase 51 HCV RESPOND 2 51 plus gemcitabine 51 phase IIb study 51 BRIM3 51 SCH # 51 BioMatrix TM 51 Phase III pivotal 51 evaluating tivozanib 51 VESTASYNC 51 randomized #:#:# 51 fistulizing Crohn disease 51 Randomized Phase 51 telmisartan 51 double blinded placebo 51 PRE SURGE 51 Drug Eluting Stents 51 Phase III confirmatory 51 CYPHER ® Stent 51 CLL8 51 AVOREN 51 LITHE 51 blind randomized controlled 51 COPERNICUS 51 LEXIVA r 51 Multicenter Automatic Defibrillator Implantation 51 CYPHER Stent 51 everolimus eluting stents 51 Endoprosthesis 51 OZURDEX 51 concurrent chemoradiation 51 Phase IIa trial 51 bosentan 50 Phase Ia 50 subcutaneously administered 50 Intervention Effectiveness 50 Aflibercept 50 CYPHER R stent 50 TAXUS Express 50 transfemoral 50 rosuvastatin #mg 50 plus COPEGUS 50 noninferior 50 APTIVUS 50 ACTEMRA 50 Phase IIIb study 50 Phase III multicenter 50 Carotid 50 CBLC# 50 Phase 2b 50 GAMMAGARD 50 blinded randomized placebo controlled 50 prospective observational 50 IN.PACT 50 Tarceva TM 50 randomized #:# 50 blind placebo controlled 50 Randomized controlled 50 Thrombolysis 50 Phase III randomized controlled 50 AIM HIGH 50 INCB# [001] 50 FAME Study 50 MIST II 50 treatment naive genotype 50 ORMD 50 neratinib 50 LUX Lung 50 arzoxifene 50 TM Everolimus Eluting 50 dosing cohorts 50 MOTIVATE 50 drug eluting coronary stent 50 TRITON TIMI 50 PROACT 50 placebo controlled dose escalation 50 Pivotal Phase 50 Phase 1b clinical trials 50 Phase Ib study 50 ToGA 50 comparator arm 50 LATITUDE 50 lixisenatide 50 Phase #/#a 50 sunitinib malate 50 AVADO 50 Phase III 50 Zemplar Capsules 50 TAXUS ATLAS Small 50 antiretroviral naïve 50 PROMUS R 50 PRECiSE 50 tocilizumab 50 renal artery stenting 50 carotid artery stenting 50 ARCOXIA 50 TAXUS ® 50 Long Term Efficacy 50 IRESSA 50 AIR CF1 50 Combination REOLYSIN R 50 Augment Injectable Bone Graft 50 dosage regimens 50 Novo TTF 50 docetaxel Taxotere R 50 DAPT 50 Amrubicin 50 ritonavir boosted 50 dose escalation trial 50 ZYBRESTAT 50 PHASE III 50 unfractionated heparin UFH 50 STARFlex R 50 Zilver PTX 50 Arimidex Tamoxifen Alone 50 ribavirin RBV 50 Severe Sepsis 50 ExTRACT TIMI 49 ACCOMPLISH 49 riociguat 49 Phase 2b clinical 49 azilsartan medoxomil 49 rosuvastatin 49 multicentre prospective 49 multicenter randomized Phase 49 CRESTOR #mg 49 Phase III Clinical Trials 49 ascending dose study 49 Endeavor stent 49 Ceplene/IL-2 49 galiximab 49 secondary efficacy endpoints 49 VELCADE melphalan 49 ANCHOR trial 49 ONTARGET R 49 double blind placebo 49 CIMZIA ™ 49 Pivotal Phase III 49 Phase 1b dose escalation 49 Elitek 49 Pharmacokinetic 49 randomized 49 Investigational Device Exemption IDE 49 NSABP B 49 Feasibility Trial 49 Phase #b/#a 49 IIa clinical 49 FOLFOX6 chemotherapy regimen 49 dose escalation phase 49 relapsed refractory multiple myeloma 49 maximally tolerated dose 49 Valsartan 49 Telmisartan 49 Protelos 49 MADIT CRT 49 randomized Phase 49 primary patency 49 Vascular Wrap 49 LUMINATE 49 Phase IIb III 49 Self Expanding Stent 49 pivotal Phase III 49 Phase IIB 49 XIENCE TM 49 HuMax EGFr 49 HCV SPRINT 49 dose dose escalation 49 Zenvia Phase III 49 Xelox 49 II Clinical Trial 49 rALLy 49 AIR2 Trial 49 REYATAZ r 49 CYPHER SELECT TM 49 Scandinavian Cardiac Outcomes 49 EQUIP OB 49 Endeavor DES 49 Endarterectomy 49 DURATION 49 TAXUS R 49 label dose escalation 49 RELIANT 49 VADT 49 Phase 2b clinical trials 49 Angiographic 49 ENDEAVOR IV clinical 49 Everolimus Eluting Coronary Stent 49 XIENCE V demonstrated 49 CELLO 49 PERSEUS clinical program 49 Phase 2a trial 49 randomized double 49 ascending dose 49 Tocilizumab 49 Phase IIb 49 MEND CABG II 49 Dr. Kandzari 49 Betaferon ® 49 PROTEGE 49 oral deforolimus 49 daily Infergen 49 Phase III ADT 49 Spine Patient Outcomes 49 Phase III VISTA 49 NSABP C 49 catheter occlusion CO 49 Phase III Clinical Trial 49 GORE VIABAHN Endoprosthesis 49 paclitaxel eluting coronary stent 49 LCP AtorFen 49 plus dexamethasone 49 NATRECOR R 49 placebo controlled studies 49 carboplatin paclitaxel 49 Stenting 49 Raloxifene Evaluation MORE 49 ARIXTRA 49 placebo controlled multicenter 49 ALSYMPCA 49 STOP AF 49 Ranolazine 49 Phase 2b randomized 49 SORT OUT III 49 SANTE 48 R# #mg BID 48 trastuzumab emtansine T DM1 48 Phase IIb clinical 48 prospective nonrandomized 48 Platelet Inhibition 48 vidofludimus 48 Randomized Study 48 lorcaserin Phase 48 BARI 2D 48 VITALITY 48 multicenter study 48 TAXUS Element 48 Combo Stent 48 Multicenter Phase 48 vorinostat 48 PreCISe 48 cariprazine 48 ALGRX 48 Engerix B 48 Mycophenolate Mofetil 48 Stent Thrombosis 48 CROSSER 48 multicentre study 48 Trial Evaluating 48 Initiate Phase 48 SYNTAX trial 48 NAVISTAR R 48 relapsed MM 48 Study Evaluating 48 paclitaxel eluting 48 pharmacodynamic effects 48 trodusquemine 48 Quinamed 48 drug eluting stent 48 tolerability 48 demonstrated clinically meaningful 48 bioabsorbable stent 48 prospectively randomized 48 TAXUS Express2 Paclitaxel Eluting 48 OZURDEX ® 48 NeuroFlo 48 Phase III HEAT 48 randomized blinded placebo 48 pegylated interferon alfa 2a 48 Ereska 48 peginterferon alfa 2b 48 NLX P# 48 TAXUS Liberté stent 48 RIO Diabetes 48 MADIT CRT trial 48 symptomatic BPH 48 satraplatin Phase 48 CHAMPION PCI 48 ZYBRESTAT fosbretabulin 48 PROMUS 48 IFN α 48 Vascugel 48 IMPACT DCM 48 adult chronic ITP 48 coronary drug eluting 48 EmbraceAC 48 clevidipine 48 PRIMO CABG2 48 romidepsin 48 Tolvaptan 48 substudy 48 COPAXONE R 48 Acute Decompensated Heart Failure 48 #mg BID [001] 48 TELCYTA 48 desvenlafaxine succinate 48 Phase #b/#a clinical 48 Taxotere ® 48 ibandronate 48 Pegasys ® 48 CABERNET 48 #mg QD [002] 48 confirmatory Phase III 48 certolizumab 48 rALLy trial 48 IMPACT IMmunotherapy 48 fidaxomicin Phase 3 48 Observational Study 48 liposome injection 48 PREZISTA r 48 Phase 2b trial 48 retrospective observational study 48 paclitaxel carboplatin 48 lopinavir r 48 Femara letrozole 48 rivaroxaban 48 V Everolimus Eluting Coronary 48 Clinical Outcomes Utilizing Revascularization 48 BRAF inhibitor 48 MYTHOS trial 48 ACCORD Lipid 48 Randomized 48 evaluable 48 relapsing remitting MS RRMS 48 Secondary endpoints 48 nab paclitaxel 48 BioSTAR R 48 evaluating Vectibix 48 REMEDIAL II 48 Cardiac Resynchronization Therapy 48 everolimus 48 mg/m2 cohort 48 Levacor TM 48 Zyclara 48 Phase IIa 47 #mg q8h 47 specified primary endpoint 47 Ascendra transapical delivery 47 controlled multicenter Phase 47 JAK inhibitor 47 fluvastatin 47 Emboli Capture Guidewire 47 pharmacodynamics 47 RG# ITMN 47 CIMZIA TM 47 Resolute stent 47 axitinib 47 TASQ 47 Meets Primary Endpoint 47 CALGB 47 confirmatory clinical 47 REVEAL Registry 47 MabCampath 47 Trandolapril 47 XYOTAX TM 47 FOLFIRI chemotherapy 47 confirmatory Phase 47 dose cohorts 47 Endurant 47 phase III ACCLAIM 47 Proxinium TM 47 Traficet EN 47 Controlled Trial 47 canakinumab 47 GORE TAG ® 47 STRIDE PD 47 tapentadol ER 47 PROMUS ® 47 Primary endpoints 47 Xerecept 47 registrational trial 47 telaprevir dosing 47 ORENCIA ® 47 Systemic Sclerosis 47 ceftazidime 47 lacosamide 47 MoxDuo 47 CD HORIZON 47 Diabetic Macular Edema 47 MIVI III 47 RoACTEMRA 47 EXCITE 47 Recurrent Glioblastoma 47 Aeroquin 47 CYPHER stent 47 Percutaneous Coronary Intervention 47 novel VDA molecule 47 STEALTH C 47 Multicenter Randomized Double 47 mg administered orally 47 Placebo controlled 47 Plicera 47 MGuard ™ 47 CRLX# 47 Refractory Angina 47 pharmacokinetic pharmacodynamic 47 ZACTIMA 47 UPLYSO 47 evaluable subjects 47 patients undergoing percutaneous 47 liposomal formulation 47 prucalopride 47 PEGylated interferon beta 1a 47 PTNS 47 clinical pharmacology studies 47 RELOVAIR ™ 47 angiotensin receptor blocker ARB 47 evaluating mipomersen 47 Hsp# Inhibitor 47 Randomized Phase II 47 CYPHER 47 ADMIRE HF 47 Left Ventricular Dysfunction 47 Pemetrexed 47 PROMUS Element 47 relapsed myeloma 47 carotid stent 47 efficacy endpoints 47 induced macular edema 47 cortical stimulation 47 rilonacept 47 EXPLORE Xa 47 RRMS patients 47 oncolytic vaccine 47 Ozarelix 47 pegylated liposomal doxorubicin 47 inhaled treprostinil 47 KRN# 47 observer blinded randomized 47 Cx# [002] 47 fostamatinib 47 phase IIb trial 47 Randomized Double Blind 47 Bosutinib 47 COU AA 47 Phase IIb Trial 47 Phase III ThermoDox 47 dose escalation 47 afatinib 47 PROSTVAC TM 47 MitraClip 47 PROPEL 47 WallFlex Biliary RX 47 telaprevir dosed 47 null responder HCV 47 RenalGuard System TM 47 LEVADEX 47 tanespimycin 47 efficacy tolerability 47 RELIANT trial 47 GEM OS2 47 Drug eluting stent 47 Randomized Double blind 47 postmenopausal osteoporotic women 47 MedPulser 47 PROWESS 47 MYDICAR ® 47 CABANA 47 dose escalation study 47 Phase 2a 47 CURRENT OASIS 7 47 GSMA IPX 47 Cypher Sirolimus 47 Taxus Liberte 47 diabetic neuropathic pain 47 abiraterone acetate 47 bepotastine besilate nasal spray 47 SENTINEL 47 sipuleucel T 47 Taxotere R 47 sorafenib Nexavar ® 47 REMINYL ® 47 SIMPADICO 47 CANCIDAS 47 bortezomib Velcade R 47 DUROS 47 TMC# [002] 47 darunavir r 47 Placebo Controlled 47 Clinical Trial Evaluating 47 AVERROES 47 Bronchitol 47 amrubicin 47 Levacor 47 #mg QD [001] 47 carotid artery stenting CAS 47 ASSERT 47 multivessel disease 47 Completes Enrollment 47 brivaracetam 47 #:# randomization 47 mTOR inhibitor 47 Proellex TM 46 elacytarabine 46 Zilver PTX stent 46 unblinding 46 olmesartan 46 RE LY trial 46 DEFER 46 Double Blind Placebo 46 ORACLE MS 46 huC# DM4 46 anastrazole 46 Aplidin R 46 Pegasys plus Copegus 46 Transplant BTT 46 Phase IIb kidney transplant 46 recurrent malignant glioma 46 TYKERB 46 atazanavir ritonavir 46 recurrent malignant gliomas 46 Zenvia ™ 46 HeartMate R 46 PF # [001] 46 rilpivirine 46 FlutiformTM 46 ABC/3TC 46 ISIS # 46 neoadjuvant 46 VALOR 46 somatostatin analog 46 Medtronic Endeavor 46 elotuzumab 46 stent BMS 46 decitabine 46 ISENTRESS 46 Multicentre 46 LCP Tacro 46 Phase III clinical 46 EDEMA4 46 Randomized Double Blind Placebo 46 RezularTM 46 Reolysin 46 TO AVOID PREGNANCY WHILE 46 IIIa inhibitor 46 Taxus Liberte stent 46 somatostatin analogue 46 alfa 2a 46 bevacizumab Avastin ® 46 cangrelor 46 number NCT# ClinicalTrials.gov 46 Atom Stent 46 CYPHER ® 46 Tanespimycin 46 beta 1a 46 Delcath Phase III 46 Medtronic CoreValve 46 Angiox R 46 ENGAGE AF TIMI 46 ADVATE 46 paclitaxel poliglumex 46 alvespimycin 46 subcutaneous SC 46 pharmacokinetic profiles 46 Cotara 46 zotarolimus 46 glufosfamide 46 placebo controlled trials 46 SCD HeFT 46 biliary tract cancer 46 PREZISTA ritonavir 46 Aneurysm Repair 46 Rosuvastatin 46 Platinol ® cisplatin 46 lasofoxifene 46 diclofenac sodium 46 mg QD 46 non valvular atrial 46 recurrent glioma 46 events AEs 46 controlled dose escalation 46 secondary efficacy endpoint 46 Screening Trial 46 primary endpoints 46 Eluting Stent 46 catheter occlusion 46 Polyp Prevention Trial 46 single ascending dose 46 Controlled Study 46 naïve HCV 46 blinded randomized controlled 46 Hyphanox 46 AVASTIN 46 Ophena TM 46 Betaferon R 46 transapical 46 Heparin Bioactive Surface 46 viral kinetics 46 HORIZONS 46 oxycodone CR 46 LPV r 46 VICTOR E1 46 Phase #b/#a trial 46 rapid virologic response 46 label multicenter randomized 46 Epanova 46 Teriflunomide 46 Phase IIb trial 46 evaluating Actimmune 46 lomitapide 46 standard chemotherapy regimen 46 Androxal TM 46 labial herpes 46 efficacy 46 darunavir ritonavir 46 IIa clinical trial 46 XGEVA 46 oral diclofenac 46 BST CarGel 46 safety tolerability pharmacokinetics 46 PREOS R 46 Sideguard 46 sorafenib Nexavar 46 Randomized Controlled 46 Diabetic Macular Edema DME 46 APEX AMI trial 46 phase IIb III 46 alvimopan 46 Elagolix 46 Metabolic Efficiency 46 Resynchronization 46 NYHA Class II 46 Anti Platelet 46 ILUVIEN ® 46 HPTN 46 Tiotropium 46 pharmacokinetic 46 subcutaneous PRO 46 Aplidin 46 TQT 46 mycophenolate mofetil 46 eptifibatide 46 INT# [002] 46 PEG INTRON R 46 volociximab 46 Cloretazine ® 46 refractory metastatic colorectal cancer 46 plus methotrexate 46 ARDIS 46 RSD# oral 46 atrasentan 46 mapatumumab 46 Dose Ranging Study 46 Blind Placebo Controlled 46 INTELENCE 46 Phase III Trial 46 intravenous dosing 46 SpideRX 46 fluticasone furoate 46 cetrorelix pamoate 46 primary endpoint 46 Xanafide 46 BRILINTA 46 Raptiva r 46 omega interferon 46 NSABP 46 investigational protease inhibitor 46 pharmacodynamic PD 46 European Sepsis Trial 46 candesartan cilexetil 46 By JENNIFER LEARN 46 VESTAsync 46 placebo controlled clinical trials 46 CCX# 46 cardiac resynchronisation therapy 46 APPRAISE 46 de novo kidney transplant 46 bevacizumab Avastin 46 ticagrelor 46 GRAVITAS trial 45 PREVENT IV 45 STELARA 45 Neupogen ® 45 plus Copegus R 45 TMC# [001] 45 CATIE AD 45 dirucotide MBP# 45 ECASS 45 thrombus aspiration 45 Custom NX R 45 efavirenz EFV 45 PFO closure 45 MVax 45 adenoma recurrence 45 randomized controlled clinical trials 45 ADAGIO study 45 registrational 45 secondary endpoint 45 bendamustine 45 Embolic Protection Device 45 IIa trial 45 DIRECT Trial 45 Pivotal Phase II 45 myoblast therapy 45 ug dose 45 GSK# [001] 45 tenofovir emtricitabine 45 Drug Eluting Stent 45 prospective multicenter study 45 XIAFLEX 45 thorough QT 45 Adalimumab 45 observational cohort 45 docetaxel Taxotere ® 45 HepaSphere 45 Ranibizumab